Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial

Abstract Background Our aim in this work is to find biomarkers to optimize therapy with IL-6 inhibitors, as not all clinical trials have shown clear benefits on mortality or mechanical ventilation progression. Given the link between delayed seroconversion and higher complication risks, we aim to tes...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	BMC Infectious Diseases
المؤلفون الرئيسيون:	José Aguareles, Carles Forné, Ana García-Casas, Guillermo Santamaría-Corral, Daniel Carnevali-Ruiz, Gabriel Sotres-Fernández, Javier T Solera, Pablo Guisado-Vasco
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2025-05-01
الموضوعات:	Tocilizumab SARS-CoV-2 COVID-19 Antibodies Serostatus IL-6 inhibitors
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12879-025-11001-6